Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
September 28 2023 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, announced today the acceptance of
five abstracts at the 2023 American College of Rheumatology’s (ACR)
annual meeting, ACR Convergence 2023, being held November 10-15,
2023, at the San Diego Convention Center in San Diego, California.
Below is the list of accepted abstracts, with links to each:
Sunday, November 12, 2023
Poster Presentation | Presented by Doruk Erkan | Abstract
#0099Title: Cell-bound Complement Activation Products in
Antiphospholipid Antibody-positive Patients Without Other Systemic
Autoimmune DiseasesSession Title: Poster Session ASession Time:
9:00 – 11:00am PT
Poster Presentation | Presented by Jennifer Rogers | Abstract
#0557Title: Longitudinal Evaluation of Cell-bound Complement
Activation Products in Patients with SLESession Title: Poster
Session ASession Time: 9:00 – 11:00am PT
Poster Presentation | Presented by Andrew Concoff| Abstract
#0575Title: The Real-World Utility of a Lupus Activity Monitoring
Panel in the United States Community Rheumatologist PracticeSession
Title: Poster Session ASession Time: 9:00 – 11:00am PT
Poster Presentation | Presented by Andrew Concoff| Abstract
#0576Title: Enhancing Systemic Lupus Erythematosus Diagnosis:
Comparative Performance Characteristics of TC4d and Anti-T-Cell
Antibodies with Conventional BiomarkersSession Title: Poster
Session ASession Time: 9:00 – 11:00am PT
Tuesday, November 14, 2023
Poster Presentation | Presented by Vasileios Kyttaris| Abstract
#2273Title: Predicting SLE Disease Activity with Blood Biomarkers:
A Step Towards Precision MedicineSession Title: Poster Session
CSession Time: 9:00 – 11:00am PT
About Exagen Inc.
Exagen is a leading provider of autoimmune testing and its
purpose as an organization is to provide clarity in autoimmune
disease decision making with the goal of improving patients’
clinical outcomes. Exagen is located in San Diego County,
California.
For more information, please visit Exagen.com and
follow @ExagenInc on X.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen’s
current beliefs and expectations. Such forward-looking statements
include, but are not limited to, statements regarding our clinical
research and development team’s scientific abstracts for
presentation at ACR Annual Conference and the potential to lead to
increased adoption of any AVISE® test. The inclusion of
forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Exagen’s
business, including, without limitation: delays in reimbursement
and coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products among rheumatologists, patients,
third-party payors and others in the medical community; Exagen’s
ability to successfully execute on its business strategies;
third-party payors not providing coverage and adequate
reimbursement for Exagen’s testing products, including Exagen’s
ability to collect on funds due; Exagen’s ability to obtain and
maintain intellectual property protection for its testing products;
regulatory developments affecting Exagen’s business; and other
risks described in Exagen’s prior press releases and Exagen’s
filings with the Securities and Exchange Commission (“SEC”),
including under the heading “Risk Factors” in Exagen’s Annual
Report on Form 10-K for the year ended December 31, 2022 and any
subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and Exagen undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525
Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024